NCT00073957View on ClinicalTrials.gov

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

January 1, 2012

Study Completion Date

January 1, 2012

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

DRUG

cytarabine

to be used for CNS prophylaxis

DRUG

liposomal cytarabine

to be used as CNS prophylaxis

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

05401

Fletcher Allen Health Care - Medical Center Campus, Burlington

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER

NCT00073957 - Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter